Corvus Pharmaceuticals Inc

Uždarymo kaina

15.25 2.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.77

Max

15.25

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+107.49% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-199M

1.1B

Ankstesnė atidarymo kaina

12.42

Ankstesnė uždarymo kaina

15.25

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-02 23:56; UTC

Macro News

FTSE 100 Index rises in after-market hours as inflation concerns ease. Positive corporate news and U.S. employment data support the upward momentum.

2026-07-02 23:56; UTC

Correlated Moves

EUR/TRY is higher in Thursday's session, supported by a modest increase since Wednesday's close. The pair remains volatile within its one-month range.

2026-07-02 23:56; UTC

ETF Constituents

The Vanguard FTSE Emerging Markets ETF was little changed in after-market hours, with INFY, TCOM, and JD contributing slight declines.

2026-07-02 23:51; UTC

Asia equity markets decline amid semiconductor sell-off, while U.S. indices rise on weak job data easing rate hike fears; European markets gain as defensive sectors lead.

2026-07-02 23:51; UTC

U.S. job growth disappoints with only 57k added in June, prompting reassessment of Fed rate hike expectations, while global markets show mixed signals amid easing inflation concerns.

2026-07-02 23:51; UTC

US equity indices rise as lower-than-expected job growth eases interest rate hike fears, while European markets gain and Asian stocks face losses.

2026-07-02 23:51; UTC

European equity markets rise on positive economic data and easing inflation, with Germany's DAX up 1.9% and Italy's unemployment hitting a record low of 5.0%.

2026-07-02 23:51; UTC

Mexico's Inflation Rate Release on July 9, 2026: Market Eyes Rising Trends Amid Tariff and Oil Price Concerns.

2026-07-02 23:51; UTC

Mexican Inflation Rate Expected to Decline Further Ahead of July 9 Release, Influencing Market Sentiment Amid Global Trends.

2026-07-02 23:51; UTC

Social Media

Fox Corp shares are lower in after-market hours despite record viewership for the U.S. Men's National Team match, averaging 24.43 million viewers.

2026-07-02 23:51; UTC

Fiserv Inc. shares are higher in after-market trading, reflecting positive sentiment following weaker-than-expected job growth data that has eased rate hike concerns.

2026-07-02 23:51; UTC

Macro News
Social Media
ETF Constituents
Correlated Moves

The KOSPI index fell sharply, impacting the iShares MSCI South Korea ETF, which remained near unchanged in after-hours trading.

2026-07-02 23:51; UTC

Lam Research Corp shares are higher in after-market trading, reflecting positive sentiment following a weaker-than-expected jobs report and tempered rate hike fears.

2026-07-02 23:51; UTC

Terra is trading higher today, continuing its upward momentum since Wednesday's close. The asset remains below its 20-day moving average.

2026-07-02 23:51; UTC

PepsiCo Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid generally positive broader market sentiment.

2026-07-02 23:46; UTC

Correlated Moves

J B Hunt Transport Services Inc shares are higher in after-market trading, following a modest increase since Thursday's close amid stable market conditions.

2026-07-02 23:46; UTC

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting a decline since Thursday's close and nearing its one-month low.

2026-07-02 23:46; UTC

Macro News
ETF Constituents
Correlated Moves

Energy Select Sector SPDR Fund declines after-market, influenced by weak U.S. employment data and slight losses among major holdings like Exxon Mobil and Chevron.

2026-07-02 23:42; UTC

U.S. Trade Deficit Expected to Widen to $78.8 Billion in May 2026 Amid Economic Uncertainties and Geopolitical Tensions

2026-07-02 23:42; UTC

U.S. Exports Data Release on July 7 Expected to Reflect Mixed Performance Amid Global Economic Challenges and Tariff Changes

2026-07-02 23:42; UTC

U.S. Imports Data Release on July 7, 2026, Expected to Reflect Strong Growth Amid Tariff Changes and Supply Chain Adjustments

2026-07-02 23:42; UTC

Canada's Trade Surplus Expected to Continue Amid Geopolitical Tensions Ahead of July 7 Data Release

2026-07-02 23:41; UTC

Correlated Moves

NXP Semiconductors NV shares are higher in after-market trading, reflecting a modest increase since Thursday's close amid gains in Skyworks Solutions Inc.

2026-07-02 23:41; UTC

NetApp Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains near its one-month trading range.

2026-07-02 23:41; UTC

News
Social Media

Meta shares rise in after-market trading as CEO Zuckerberg highlights upcoming AI benefits and announces new application Pocket, despite some setbacks.

2026-07-02 23:41; UTC

Macro News
Correlated Moves

Bitcoin reached a one-week high today, boosted by weaker U.S. employment data and optimism about Federal Reserve rate hikes. Related stocks also gained.

2026-07-02 23:36; UTC

The US Dollar Index is trading roughly flat amid routine price action. European equity markets closed positively, driven by gains in defensive sectors and pharmaceuticals.

2026-07-02 23:36; UTC

Correlated Moves
Macro News
ETF Constituents

The SPDR S&P Bank ETF is higher after hours, supported by Third Coast Bancshares' $30 million share repurchase program and mixed market performance.

2026-07-02 23:36; UTC

Kraft Heinz Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock briefly reached a session high earlier.

2026-07-02 23:32; UTC

News
Social Media

Microsoft launches AI initiative Microsoft Frontier Company with $2.5 billion backing. Shares are higher in after-market trading, continuing the broader software sector's upward trend.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

107.49% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  107.49%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat